Executive summary. Europe does not have a single medical cannabis law. Cannabis-derived medicinal products sit within the wider EU pharmaceutical framework, while cultivation, controlled-drug permissions, prescribing, reimbursement and patient access remain heavily shaped by national law. Companies therefore need two maps: the common European medicines and quality framework, and the country-specific route that determines whether a product can actually be supplied.
The EU framework is product based, not cannabis specific
At EU level, a cannabis-derived product that meets the definition of a medicinal product is subject to the same core legislation as other medicines. That means quality, safety and efficacy expectations arise from the product's intended use and regulatory route, not simply from the fact that it contains cannabis. A centrally or nationally authorised medicine requires an appropriate marketing authorisation. Other supply routes, including named-patient or special-access mechanisms, depend on national legislation and do not create a universal EU exemption.
This product-based approach means a company cannot rely on cannabis-specific precedent alone — the same evidentiary and quality bar that applies to any other medicinal product applies here, regardless of the source material.
EMA and the distinction between herbal and non-herbal routes
EMA has published terminology and questions-and-answers to clarify cannabis-derived medicinal products. A product may be presented as a herbal substance, herbal preparation, isolated cannabinoid, active substance or finished medicinal product. Those categories matter because they influence quality documentation, evidence expectations and the relevance of herbal medicinal product guidance. The existence of cannabis in a plant-derived form does not automatically make the traditional herbal registration route available.
Because the herbal and non-herbal distinction affects which guidance documents are relevant, companies should confirm their product’s classification with the target authority early, rather than assuming the traditional herbal route is automatically available.
The European Pharmacopoeia cannabis flower monograph
The European Pharmacopoeia monograph Cannabis flower (3028) became a legally binding quality standard in participating states on 1 July 2024. It provides a harmonised baseline for identity, assay and selected quality attributes. It should be read with the general monograph for herbal drugs and with applicable national or product-specific specifications. The monograph improves harmonisation, but it does not itself authorise a product or replace GMP, GACP, stability or market-specific requirements.
The Cannabis flower monograph provides a common quality reference, but it does not substitute for country-specific requirements on pesticide panels, heavy metals or additional testing that some national authorities impose beyond the monograph.
GACP, GMP and the cultivation-manufacturing interface
Cultivation and collection of herbal starting materials are generally governed through GACP principles, while pharmaceutical processing, packaging, testing and release fall under GMP. The precise transition point depends on the process and regulatory position. Drying, trimming and primary handling may sit at the interface. Companies should define the boundary explicitly in licences, quality agreements, specifications and validation plans rather than assuming that all activities at a cultivation site are automatically outside GMP.
The GACP-to-GMP interface is where EU-wide principles meet the greatest national variation in practice — the same handover point may be interpreted differently by different competent authorities, and this should be confirmed rather than assumed.
What companies should prioritise
The most efficient approach is to define the target market, product classification and supply route before building facilities or finalising a formulation. Regulatory strategy should drive the quality target product profile, manufacturing standard, stability programme, packaging and evidence package.
Companies entering the European market should prioritise country-specific regulatory mapping over a generic EU compliance programme — the practical route to patient access is determined at national, not EU, level.
Practical reference table
| Regulatory layer | What it controls | Practical implication |
|---|---|---|
| EU medicines legislation | Authorisation and medicinal-product obligations | Cannabis medicines follow the wider pharmaceutical framework |
| EU GMP/GDP | Manufacture, testing and distribution | Quality systems and licensed activities |
| European Pharmacopoeia | Legally applicable quality standards | Cannabis flower and general monographs |
| National cannabis law | Cultivation, possession, supply and prescribing | Country-specific market access |
| Controlled-drug law | Import/export permits and security | Separate licences and transaction permits |
| National reimbursement rules | Patient affordability and funding | Commercial viability varies by country |
Decision and implementation path
Common implementation mistakes
Common mistakes include choosing a country because cultivation appears attractive without confirming product access; assuming that GMP certification resolves controlled-drug permissions; using broad cannabis terminology where the active substance is not clearly defined; and relying on commercial claims that exceed the available evidence. A second recurring weakness is treating laboratories, logistics providers or cultivators as external to the pharmaceutical quality system. Outsourced work remains part of the regulated supply chain and requires qualification, agreements, performance review and change notification.
Frequently asked questions
Is there one EU medical cannabis licence?
No. Licences and permissions are granted under national systems.
Does the European Pharmacopoeia monograph authorise cannabis flower?
No. It provides a quality standard but does not create market authorisation.
Is every cannabis-derived medicine treated as a herbal medicine?
No. Classification depends on composition, presentation and regulatory route.
Can a product approved in one EU country be sold automatically in another?
Not necessarily. Mutual-recognition routes may apply to authorised medicines, but national cannabis and controlled-drug rules remain relevant.
Where should a company start?
With product classification, target market and regulatory route before facility or commercial decisions.
Primary references and guidance
- Directive 2001/83/EC on medicinal products for human use
- EMA: Questions and Answers Regarding Cannabis-derived Medicinal Products
- EMA: Compilation of Terms and Definitions for Cannabis-derived Medicinal Products
- EMA: Guideline on Quality of Herbal Medicinal Products
- EDQM: European Pharmacopoeia monograph Cannabis flower (3028)
- EU GMP Guide, Parts I and II
- EU Guidelines on Good Distribution Practice
- WHO and EMA GACP guidance
- Applicable national controlled-drug and cannabis legislation
Confirm the current effective version and national applicability before operational, medical or regulatory use.